Improving Alzheimer’s Disease Management: Updates on Patient Diagnosis and Treatment

The face of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) diagnosis and management is rapidly changing. A growing understanding of AD pathophysiology has shaped research of targeted therapies and helped clinicians better understand the causes of the disease and the utility of biomarkers. Though cognitive testing is still a critical component of diagnosis, it no longer stands alone. Biomarkers are increasingly incorporated into practice to aid in diagnosis of MCI and AD and to determine patient eligibility for recently approved targeted antiamyloid therapies. These therapies require novel clinical approaches and changes to clinic infrastructure, which can be challenging to implement. Drs Douglas Galasko and Marwan Sabbagh review recent pathophysiologic outlooks in AD, utility of biomarkers, use of antiamyloid therapies, and real-world challenges and successes in clinic infrastructure changes made to facilitate administration of novel therapies.